Delek Group’s BioLineRX BLRX Stock Holding History

Delek Group’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$134K	Buy	625 +266	+74%	+$59.7K	0.01%	216
2019 Q1	$92K	Buy	+359	New	+$105K	﹤0.01%	206

Other funds holding BLRX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

Delek Group's BLRX Position: Q2 2019 in Review

Delek Group increased its BioLineRX (BLRX) stake by 74% in Q2 2019, buying an estimated $59.7K and bringing the position to 625 shares worth $134K. The position accounts for 0.01% of the portfolio, ranked #216.

Delek Group first reported a position in BLRX in Q1 2019 and has held it in 2 quarters since. 24 funds tracked by Wall St. Rank hold BLRX as of Q2 2019.

Delek Group held 625 shares of BioLineRX worth $134K as of Q2 2019.
Delek Group bought 266 BioLineRX shares in Q2 2019, an estimated $59.7K.
BioLineRX made up 0.01% of Delek Group's portfolio in Q2 2019, its #216 holding.
Delek Group first reported a position in BioLineRX in Q1 2019 and has held it in 2 quarters since.
24 funds tracked by Wall St. Rank held BioLineRX as of Q2 2019.

Based on Delek Group's 13F filing for Q2 2019, filed 8 Aug 2019.